PII Study of Terbinafine Patch for Tinea Unguium in US Shows No Significant Difference Against Placebo in Primary Endpoint: Hisamitsu

Hisamitsu Pharmaceutical announced on May 14 that the PII clinical study of its investigational terbinafine HCl patch (development code: HTU-520) for tinea unguium patients in the US did not show a significant difference against placebo in the primary endpoint of...read more